Gelatinase B/matrix metalloproteinase-9 (MMP-9), a key regulator and effector of immunity, contains a C-terminal hemopexin domain preceded by a unique linker sequence of ~64 amino acid residues. This linker sequence is demonstrated to be an extensively O-glycosylated (OG) domain with a compact 3D structure. The OG and hemopexin domains have no influence on the cleavage efficiency of MMP-9 substrates. In contrast, the hemopexin domain contains a binding site for the cargo receptor lipoprotein receptor related protein-1 (LRP-1). Furthermore, megalin/LRP-2 is identified as a new functional receptor for the hemopexin domain of MMP-9, able to mediate the endocytosis and catabolism of the enzyme. The OG domain is required to correctly orient the hemopexin domain for inhibition by TIMP-1 and internalisation by LRP-1 and megalin. Therefore, the OG and hemopexin domains downregulate the bio-availability of active MMP-9 and the interactions with the cargo receptors are proposed to be the original function of hemopexin domains in MMPs.
Introduction
Matrix metalloproteinases (MMPs 1 ) constitute a family of Zn 2+ -dependent proteases, which share a number of conserved protein domains (1) . All MMPs consist of a propeptide and a Zn 2+ -containing active site, and most MMPs have a Cterminal hemopexin domain. Some MMPs contain additional domains, e.g. in MT-MMPs, the hemopexin domain is connected to a membrane anchor, and in MMP-2 (gelatinase A) and MMP-9 (gelatinase B), a fibronectin domain is inserted in the active site. In MMP-9, a unique linker sequence of unknown function connects the active site and the hemopexin domain, and is more than 50 amino acids long (in contrast to ~10 residues for the linker sequence in other MMPs). It has been considered to be an independent protein domain and has low homology with collagen type V (2), mainly because of its high proline-content. Since we show in the present study that it contains Olinked glycans, it is henceforth named the Oglycosylated (OG) domain. MMP-9 degrades extracellular matrix components and cleaves a variety of soluble proteins, including cytokines and chemokines. Overexpression of MMP-9 leads to inflammation, tissue destruction and pathology (3;4) . Therefore, expression of MMP-9 is highly regulated at the levels of transcription, translation and secretion. Once secreted, the activity is tightly kept in check by proenzyme latency, inhibition and catabolism. The active site can be inhibited by interaction with the Nterminal domain of the tissue inhibitors of metalloproteinases (TIMPs) (5) . In addition, the C-terminal part of TIMP-1 binds to the hemopexin domain of both the pro-and active MMP-9, leading to a high affinity interaction (6) . MMP-9 may be internalised and subsequently degraded through the cargo receptor low density lipoprotein-related receptor-1 (LRP-1 or CD91) (7) . Another regulatory system for MMP-9 activity is glycosylation (8) . Structures of N-and O-linked sugars were determined for natural MMP-9 from human neutrophils (9;10). Little information is available concerning the structures or functions of glycosylation of other MMPs, except that in MT1-MMP, the O-linked glycans on the linker peptide between the active site and the hemopexin domain are essential for the binding of TIMP-2 (11) . Besides the catalytic site, different domains of MMPs are important for the hydrolysis of particular substrates. Collagenolysis by interstitial collagenase is dependent on the hemopexin domain and linker peptide (12) . Gelatinolysis by gelatinases is more than 100-fold enhanced by the gelatin-binding fibronectin domain (13) . The hemopexin domain of MMP-2 binds monocyte chemoattractant protein-3 (MCP-3), leading to MCP-3 cleavage (14) . These and other examples have led to the concept of "exosites", which bind the substrate and confer high efficiency on the subsequent cleavage (15) . This concept is also interesting from a therapeutic point of view, since inhibition of the exosite interaction may be used to inhibit the cleavage of particular substrates while leaving other activities of the MMP unaffected. Since no data are available on the structure and functions of the OG domain and limited data on the function of the hemopexin domain of MMP-9, we aimed at studying the structural and functional aspects of these two domains by the generation of recombinant MMP-9 variants, with deletions or mutations.
Experimental procedures

Expression and purification of recombinant MMP-9 in Sf9 insect cells
The cDNA of human MMP-9, a kind gift of Dr. G.I. Goldberg (2) , was amplified by PCR with the following primers: ATATCTCGAGAGCCCCCAGACAGCGCCA GTCC ("hgelBfor", Xho-I site underlined) and AATTCCATGGCTAGTCCTCAGGGCACTGC AGG ("hgelBrev", Nco-I site underlined). After cleavage with Xho-I and Nco-I, the amplicon was inserted into the pMelBacB vector (Invitrogen Corporation, Merelbeke, Belgium) behind the polyhedrin promoter and the mellitin secretion signal, resulting in the vector pMelBacBMMP-9. The construct was checked by DNA sequence analysis. Sf9 cells were cotransfected with pMelBacBMMP-9 and the baculoviral Bac-N-Blue TM DNA (Invitrogen), according to the protocol of the manufacturer.
This results in homologous recombination between the linearized baculoviral Bac-NBlue TM DNA and pMelBacBMMP-9, generating viable recombinant viruses with the MMP-9-gene and a functional LacZ. The supernatant of the cotransfected cells was harvested after 72 h incubation at 27°C. This P1 transfection viral stock was subjected to a plaque assay in the presence of the chromogenic substrate Bluo-gal (Invitrogen). Blue recombinant virus clones were isolated and screened by PCR to detect the MMP-9 insert. Viral clones containing the insert of the correct length were expanded in Sf9 cells to form a P2 small-scale high-titer virus stock, which was further expanded to a large-scale high-titer P3 virus stock. Suspension cultures of Sf9 cells (2.10 6 cells/ml) were infected with 0.05 plaque-forming units (pfu)/cell, and the supernatant was harvested after 3 days incubation at 27°C in serum-free medium. MMP-9 was purified by gelatin-Sepharose chromatography as described (16) .
Mutagenesis of recombinant MMP-9
To generate deletion mutants of human MMP-9 lacking the hemopexin domain or the OG and hemopexin domains, a stop codon was inserted in the sequence of MMP-9 in pMelBacBMMP-9 behind the codon coding for Pro 511 or for Pro 447 , respectively. This was performed by sitedirected mutagenesis with the "Quik Change Site-Directed Mutagenesis Kit" (Stratagene, La Jolla, CA). The following primers, which contain the mutations (underlined), were used for the mutagenesis :  CTATGGTCCTCGCCCTTAACCTGAGCCAC  G  and  CGTGGCTCAGGTTAAGGGCGAGGACCAT  AG  for  MMP-9∆OGHem,  CTGTGCCTTTGAGTCCGTAGGACGATGCC  TGC and GCAGGCATCGTCCTACGGACTCAAAGGC ACAG for MMP-9∆Hem. The same strategy was used to generate a vector coding for MMP9MutEC, in which the catalytic Glu 402 and Cys 468 in the OG domain are mutated into Ala. The following primers, which contain the mutations (underlined), were used for this construct :  GCTCCCCCGACGGTCGCCCCCACCGGAC  CC  and  GGGTCCGGTGGGGGCGACCGTCGGGGGA  GC  for  mutation  of  Cys 468  and  CGTGGCGGCGCATGCGTTCGGCCACGCG  CTGG  and CCAGCGCGTGGCCGAACGCATGCGCCGC  CACG for mutation of Glu 402 . The OG domain in MMP-9∆OG was deleted using a splicing-by-overlap-extension method (17) . The coding sequence for the part of MMP-9 preceding the OG domain was amplified by PCR using the following primers: ATATCTCGAGAGCCCCCAGACAGCGCCA GTCC ("hgelBfor") and ATCGTCCACAGGGCGAGGACCATAGAGG TGCCGG ("gbdelc5r", overlap with hemopexin domain is underlined). The hemopexin domain was amplified by PCR with the primers CCTCGCCCTGTGGACGATGCCTGCAACGT GAAC ("gbdel5Fbis", overlap with OG domain is underlined) and AATTCCATGGCTAGTCCTCAGGGCACTGC AGG ("hgelBrev"). After purification, the two PCR products were mixed and again amplified using the hgelBfor and hgelBrev primers, resulting in a PCR product containing the sequence of MMP-9 without the OG domain. This PCR product was first subcloned in the pCR4-TOPO-vector (Invitrogen) in E. coli. Recombinant clones were screened and checked by DNA sequencing analysis. A clone without unwanted mutations was excised with Xho-I and Nco-I and ligated into pMelBacB, resulting in the vector pMelBacBMMP-9∆OG. The insert was checked again by DNA sequencing. Each of these constructs was expressed and purified in the same way as for intact MMP-9 (see above).
Activation of recombinant MMP-9 variants
MMP-9 variants (10 µM) were activated with 0.1 µM recombinant catalytic domain of human stromelysin-1 (Calbiochem, Germany), without the presence of APMA, during 90 min at 37°C in assay buffer (100 mM Tris/HCl pH 7.4, 100 mM NaCl, 10 mM CaCl 2). The activity at different time intervals was monitored by gelatin zymography and with a fluorogenic substrate conversion assay (18) .
Binding of recombinant MMP-9 to lectins
Binding of MMP-9 variants to the lectins Helix pomatia agglutinin (HPA, specific for Ser-or Thr-linked GalNAc) and jacalin (specific for Gal-GalNAc) was tested using HPA-and jacalin-agarose (Sigma, Bornem, Belgium) chromatography. 100 µg of the MMP-9 variants in 50 mM Tris/HCl pH 7.4 and 50 mM NaCl were loaded on the lectin-agarose column.
Bound MMP-9 was eluted with a gradient of 0-400 mM GlcNAc for HPA-agarose and 0-100 mM lactose for jacalin-agarose. Binding and elution was monitored by UV absorption at 254 nm and by zymography analysis of the flowthrough and eluent.
Detailed glycosylation analysis of recombinant MMP-9
In-gel enzymatic release of N-linked glycans 10 µg of the MMP-9 variants were reduced and alkylated prior to SDS-PAGE. Gel bands were cut out and N-linked glycans extracted as described (19 Normal Phase HPLC NP-HPLC separations were performed on a 2690 Alliance separation module (Waters, Milford, MA) equipped with a 474 fluorescent detector and fitted with a 4.6 x 250 mm TSKgel amide-80 column (Anachem, Luton, Beds, UK). Gradient conditions and detection were as described previously (22;23) . The system was calibrated against a standard dextran hydrolysate ladder so that the retention time for individual glycans could be converted to glucose units (GU) (22) . Oligosaccharide structures were assigned by reference to the GU values of a database of standard sugars (23) .
Glycan analysis by liquid chromatographyelectrospray ionisation-mass spectrometry LC-ESI-MS
2-AB labelled glycans were analysed using an LC packings Ultimate HPLC equipped with a Famos autosampler (Dionex Ltd, Leeds, UK) interfaced with a Q-Tof Ultima Global mass spectrometer (Waters-Micromass, Manchester, UK). Chromatographic separation was achieved using a 2 x 250 mm, microbore NP-HPLC TSK gel Amide-80 column (Hichrome), 50 mM ammonium formate pH 4.4 (Solvent A) and acetonitrile (Solvent B), with a gradient of 20 to 70% Solvent A over 100 min at a flow rate of 40 µL/min. The mass spectrometer was operated in positive ion mode with 3 kV capillary voltage; RF lens 60; source temp 100°C; desolvation temp 150°C; cone gas flow 50 L/Hr; and, desolvation gas flow 450 L/Hr. (23) .
Digestion of MMP-9 substrates
To estimate the cleavage efficiency of various substrates by the different MMP-9 variants, denatured bovine collagen II (24), MMP-8-cleaved native collagen II (25), α1-antitrypsin inhibitor (R&D Systems, Abingdon, UK; 0.5 µM) (26) , mouse eye extract containing βB1-crystallin (27) , recombinant intact mouse granulocyte chemotactic protein-2 (mGCP-2/LIX, Peprotech Inc, Rocky Hill, NJ; 2 µM) (28), recombinant interleukin-8 (IL-8, Peprotech, 2 µM) (29), galectin-3 (R&D Systems, 30 µg/ml) (30) , soluble recombinant ICAM-1/Fc chimera (R&D Systems, 30 µg/ml) (31), soluble recombinant CD25/Fc chimera (R&D Systems, 30 µg/ml) (32), human plasminogen (R&D Systems, 30 µg/ml) (33), human platelet SPARC (Calbiochem, 1 µM) (34) or recombinant monocyte chemotactic protein-3 (MCP-3, Peprotech, 0.5 µM) was incubated in 100 mM Tris/HCl pH 7.4, 100 mM NaCl, 10 mM CaCl 2 with different concentrations of activated MMP-9 variants at 37°C. As negative control for the cleavage by MMP-9, the substrates were incubated under identical conditions with the corresponding concentration of recombinant catalytic domain of human MMP-3, used for the activation of MMP-9 (1/100 of the molar concentration of MMP-9). Digestion was stopped by the addition of reducing SDS-PAGE loading buffer and the samples were analysed by SDS-PAGE. To compare the cleavage efficiencies, it was estimated from the gels at which concentration of the MMP-9 variants the substrate was cleaved for 50 %. For IL-8 and mGCP-2/LIX, the cleavage efficiency was determined by mass spectrometry analysis as described (28) .
SPR-analysis of the binding of MMP-9 variants to TIMP-1, LRP-1 and megalin
The binding to TIMP-1, LRP-1 and megalin was studied by SPR analysis on a Biacore 3000 instrument (Biacore, Sweden) as follows. Biacore sensor chips type CM5 were activated with a 1:1 mixture of 0.2 M N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide and 0.05 M N-hydroxysuccimide in water according the manufacturer. LRP was immobilized at a concentration 15 µg/ml in 10 mM sodium acetate pH 3.0. Megalin was immobilized at a concentration 10 µg/ml in 10 mM sodium acetate pH 4.5. TIMP-1 was immobilized at a concentration 10 µg/ml in 10 mM sodium acetate pH 6.0. Remaining binding sites were 
Endocytosis analysis
Cellular uptake and degradation of natural MMP-9 from human neutrophils and MMP-9fl was investigated in Brown Norway rat yolk sac sarcoma epithelial cells (BN16) and cos-1 cells as described previously (35;36) . BN16 and cos-1 endogenously express the megalin and LRP-1 receptor, respectively. Briefly, cells were grown to confluence in 24-well plates (Nunc, Denmark) in Dulbecco modified Eagle medium (DMEM; Invitrogen, Denmark) containing 10% fetal calf serum (FCS). After washing in phosphatebuffered saline (PBS), pH 7.4, cells were incubated with 125 I-labeled MMP-9fl or 125 Ilabeled natural MMP-9 (3000 cpm/well ~ 0.5 ng) in serum-free DMEM containing 1% bovine serum albumin (BSA). In the inhibition studies, BN16 and cos-1 cells were incubated for 30 min with receptor-associated protein (RAP; 100 µg/ml), polyclonal rabbit anti-megalin (100 µg/ml) and anti-LRP-1 (300 µg/ml) antibody, respectively, or non-immune anti-myoglobin antibody (100 µg/ml or 300 µg/ml) prior to addition of radiolabeled protein. Degradation of 125 I-labeled MMP-9fl or 125 I-labeled natural MMP-9 in lysosomes was inhibited by addition of 300 µM chloroquine (Fluka) and leupeptin (Sigma). After incubation, the medium was harvested and tricloroacetic acid (TCA) was added to it. In the meantime, the cells were washed and hereafter lysed to allow determination of cell-associated radioactivity. Radioactivity in the TCA-soluble fraction of the medium represented degraded protein.
Analytical ultracentrifugation
Sedimentation-velocity experiments were carried out using a Beckman Optima XL-A analytical ultracentrifuge equipped with absorbance optics with an An60Ti rotor. Samples were analysed at concentrations between 0.075 and 0.3 mg/ml in 100 mM Tris/HCl, pH 7.4, 100 mM NaCl and 10 mM CaCl 2 at 50,000 rev./min. Scans were collected at 150 s intervals at 230 nm. Sedimentation coefficients were determined using the time derivative method (37) and were corrected for the effects of buffer composition. The partial specific volume of each protein was calculated from its amino acid and carbohydrate composition. The theoretical sedimentation coefficients of various model structures were calculated using the program HYDROPRO (38) .
Molecular modelling
Molecular modelling was performed on a Silicon Graphics Fuel workstation using InsightII and Discover software (Accelrys Inc., San Diego, USA). Figures were produced using the program Molscript (39) . The molecular models of MMP-9 and the constructs were based on the crystal structure of the N-terminal domains of MMP-9 (40) and the hemopexin domain in the crystal structure of MMP-2 (41) . Various models of the OG domain were generated to link the N-and Cterminal domains. The fully extended model of OG domain was built using InsightII and then restrained simulated annealing was used to generate structures of an average extension of 2.6 Å per residue (10) . The extended model of OG domain allowing for the disulphide bond between the OG domain and the hemopexin domain was generated in a similar way, but in addition fixing the distance between Cys 468 and the C-terminal residue of the OG domain. Compact models of the OG domain were generated by positioning the N-terminal and Cterminal domains as required to obtain a distance constraint between the first and last residue of the OG domain. In each case, the N-terminal and C-terminal domains were then added before a final round of energy minimisation. N-linked and O-linked glycan structures, chosen on the basis of the sequencing results, were generated using the database of glycosidic linkage conformations (42) and in vacuo energy minimisation to relieve unfavourable steric interactions. For the Nlinked glycans, Asn-GlcNAc linkage conformations were based on the observed range of crystallographic values (43) , the torsion angles around the Asn Cα-Cβ and Cβ-Cγ bonds then being adjusted to eliminate unfavourable steric interactions between the glycans and the protein surface.
Results
Expression and purification of recombinant domain variants of MMP-9
Five recombinant protein variants of gelatinase B/MMP-9 were generated as described in the materials and methods section ( Figure 1A) . Each of the mutants retained its affinity for gelatin and was therefore purified to homogeneity in a similar way as the full-length enzyme, i.e. by substrate-affinity chromatography on gelatinSepharose.
Molecular weight and dimerisation of the recombinant variants of MMP-9
Reducing and non-reducing SDS-PAGE tests were used to determine relative molecular weight and dimerisation patterns of the different recombinant variants of MMP-9 ( Figure 1B ). Full-length recombinant MMP-9 (MMP-9fl) migrated at a slightly lower position than natural MMP-9 from human neutrophils, probably because of differences in glycosylation (see further). Interestingly, deletion of the OG or the hemopexin domain resulted in a similar decrease in MW, although the OG domain is only 64 amino acids long, whereas the hemopexin domain contains 196 amino acids. This finding might be explained by the O-glycosylation of the OG domain (see further). An interesting feature of MMP-9 is the formation of dimers/multimers, which are SDSresistant but can be dissociated by reduction. In contrast to the variants containing the OG domain, MMP-9∆OG and MMP-9∆OGHem showed only monomers on non-reducing SDS-PAGE and in analytical ultracentrifugation experiments (see below). This indicates that the OG domain is essential and sufficient for dimerisation/multimerisation. Though, the single cysteine residue in the OG domain, absent in MMP-9mutEC, is not essential for dimerisation/multimerisation. The exact mechanisms of dimerisation remain therefore unknown. 
Presence of abundant O-linked glycans attached to the OG domain
The OG domain of MMP-9 is unique, as it is absent in all other MMPs. Its sequence contains several Pro-residues, explaining a low homology with collagen type V (2). However, this domain lacks the typical collagen motif with Glyrepetition at every third residue. In contrast, it contains 12 repeats of the sequence Thr/SerXxx-Xxx-Pro. Since O-glycosylation occurs often on Thr or Ser when a Pro-residue is just in front of or three residues behind these Thr or Ser (45), such repeats are good candidates for Oglycosylation. Analysis of the MMP-9 sequence by the NetOGlyc server (46) , and comparison with those of all other MMPs, also revealed that the OG domain, and only this domain in MMP-9, probably contains abundant attachment sites for O-linked oligosaccharides (data not shown). To test this hypothesis, the binding of intact and deletion variants of recombinant MMP-9 to two lectins, specific for the most commonly found O-linked glycans on proteins expressed in Sf9 cells (Helix pomatia agglutinin, HPA, specific for Ser-or Thr-linked GalNAc, and jacalin, specific for Gal-GalNAc), was analysed. No binding to jacalin was observed, but all MMP9fl bound to HPA-agarose. MMP-9∆Hem bound similarly to HPA-agarose, but MMP-9∆OG and MMP-9∆OGHem did not bind to HPA (data not shown). This shows that the OG domain is Oglycosylated, while O-glycans are most likely absent on the other domains of MMP-9. These results were confirmed by a detailed glycosylation analysis of MMP-9fl and the different deletion mutants. The glycans were released from the MMP-9 variants by ammoniabased β-elimination, fluorescently labelled with 2AB and analyzed by NP-HPLC and LC-MS analysis (Figure 3 
Sedimentation analysis and molecular modelling of the MMP-9 variants shows that the OG domain is not extended
The crystal structures of the aminoterminal part and the hemopexin domain of MMP-9 have been determined separately. However, nothing is known about the three dimensional structure of the OG domain. Presumably, the multiple Olinked sugars strongly influence the 3D structure of this domain. Furthermore, the presence of a cysteine (Cys 468 ) in this domain may impose additional constraints to the 3D structure. It seems reasonable to assume that, in monomers, Cys468 forms a disulfide bridge with Cys674 in the fourth blade of the hemopexin domain, since these two cysteines are the only ones in MMP-9 for which the coupling cysteine is not known. Different models were generated in silico, with different degrees of extension/compactness of the OG domain (figure 4). To estimate which of the different models is most realistic, sedimentation coefficients of the different recombinant MMP-9 variants were determined by analytical ultracentrifugation and compared to the in silico calculated sedimentation coefficients of the different models ( Table 1) . The experimentally obtained sedimentation constants exclude the possibility of extended conformations and are consistent with the presence of a disulfide bridge between Cys 468 and Cys 674 . This disulphide bridge, however, remains to be proven. In addition, mutation of Cys468 (in MMP-9MutEC) or deletion of the hemopexin domain (MMP-9∆Hem) do not lead to a fully extended conformation, showing that the possible Cys 468 -Cys 674 disulfide bridge is not essential for a (partially) folded conformation of the OG domain.
Comparison of the catalytic activities of domain mutants of MMP-9
Exosites are important for the efficient cleavage of a number of substrates by some MMPs (15). Therefore, it is possible that the hemopexin and OG domains of MMP-9 also contain exosites enhancing the cleavage of particular substrates. To test this hypothesis, the different variants were activated with the catalytic domain of MMP-3. The activation reaction progressed similarly for the different variants (data not shown). Subsequently, the cleavages of a number of known substrates by the different activated deletion variants were compared (Table 2) . No significant differences were observed. Another theoretical possibility was that the OG domain might create a distance between the hemopexin domain and the catalytic site, thereby preventing the cleavage of e.g. MCP-3 bound to the hemopexin domain. Therefore, the cleavage of MCP-3 with the different variants was tested. No cleavage was observed, even with MMP-9∆OG, although the latter mutant structurally resembles MMP-2, which efficiently cleaves MCP-3 (14) .
Both the OG and hemopexin domains of MMP-9 are critical for the interaction with TIMP-1
The activity of MMP-9 is regulated in several ways, including inhibition by TIMPs. TIMP-1 efficiently inhibits MMP-9, because it does not only bind with its N-terminus into the active site, but also with its C-terminal domain to the hemopexin domain of MMP-9 (6). The role of the OG domain in this context has not been studied yet. Therefore, the binding of the different recombinant proMMP-9 variants to TIMP-1 was compared by surface plasmon resonance ( Figure 5 and Table 3 ). As expected, proMMP-9∆Hem and proMMP-9∆OGHem showed no binding to TIMP-1. Unexpectedly, the binding affinity of proMMP-9∆OG for TIMP-1 was ~4-fold lower. This result reinforces the idea that the OG domain of MMP-9 is important for optimal binding of TIMP-1, suggesting that in proMMP-9∆OG, the hemopexin domain is too close to the N-terminal domains leading to steric hindering of TIMP-1 binding.
LRP-1 binds MMP-9 through its hemopexin domain
Another regulation mechanism for MMP-9 is its removal from extracellular fluids by binding to LRP-1, followed by internalisation and degradation (7) . LRP-1 expressing cos-1 cells were indeed found to bind, internalise and degrade both natural and recombinant MMP-9. This could be inhibited by the receptorassociated protein (RAP) and by LRP-1-specific antibodies, confirming the involvement of LRP-1 ( Figure 6 ). To determine which domain(s) of MMP-9 are responsible for the binding to LRP-1, the different variants of MMP-9 were analysed for binding to LRP-1 with the use of surface plasmon resonance (figure 7 and Table  4 ). MMP-9fl bound LRP-1 with high affinity. However, deletion of the hemopexin domain (in MMP-9∆Hem and MMP-9∆OGHem) resulted in the loss of binding. This indicates that the binding site for LRP-1 resides in the hemopexin domain of MMP-9.
The OG domain optimises LRP-1 binding
Similar to the binding of MMP-9 to TIMP-1, deletion of the OG domain in MMP-9∆OG resulted in a significantly decreased affinity for LRP-1 (Table 4 ). This suggests that the OG domain is important for the correct orientation of the hemopexin domain. However, the binding sites for LPR-1 and TIMP-1 are unlikely to overlap, since proMMP-9 from THP-1 cells, which is complexed to TIMP-1 (47), binds with similar affinity to LRP-1 as uncomplexed MMP-9 ( Figure 7 and Table 4 ).
Identification of megalin/LRP-2 as a new functional endocytotic receptor for MMP-9
Megalin/LRP-2 is a receptor from the LDLreceptor family, similar to LRP-1. Recently, it was shown to bind neutrophil gelatinase Bassociated lipocalin (NGAL) (35) . Since NGAL also occurs as a complex with MMP-9 in neutrophils, it was interesting to analyse whether megalin would also bind neutrophil MMP-9, and also recombinant human MMP-9, which does not contain NGAL. Therefore, BN16 rat yolk sac cells, which express megalin, were incubated with radioactively labelled MMP-9, and the internalization of the enzyme was analyzed. Significant internalisation of both recombinant and natural MMP-9 was detected and was followed by degradation ( figure 8 ). The internalisation could be inhibited with RAP and with anti-megalin antibodies, indicating the essential role of megalin.
Megalin binds MMP-9 through its hemopexin domain
To determine whether MMP-9 binds directly to megalin and to investigate which domain(s) of MMP-9 are responsible for this binding, the affinities of the different variants of MMP-9 for megalin were analysed with the use of surface plasmon resonance ( Figure 9 and Table 5 ). Natural neutrophil MMP-9, partially complexed with NGAL, THP-1 MMP-9, and recombinant MMP-9fl bound to megalin with similar affinities. These data on the binding and internalisation of MMP-9 define megalin as a new functional receptor for MMP-9. A similar pattern of hemopexin and OG domain-dependent interactions was observed as for the binding of TIMP-1 and LRP-1, indicating that the tertiary structure of the OG domain optimises the functionality of MMP-9 binding to TIMP-1, LRP-1 and megalin.
Discussion
Natural MMP-9 produced by neutrophils is a heavily glycosylated protein. Approximately 85% of the glycans on natural MMP-9 are Olinked, and the remaining 15% are N-linked sugars (9) . In the supposition that the numbers of N-and O-linked glycans are comparable in natural and recombinant MMP-9, the combination of the relative ratio between N-and O-linked sugars (85:15) and the presence of 2 Nlinked sugars would suggest that more than 10 O-linked sugars may be present. By using recombinant DNA technology and glycosylation analysis, a series of domain mutants were engineered and compared, indicating that the Olinked oligosaccharides are attached to the unique OG domain for which no function was known to date. This corresponds with the known primary sequence preferences of O-linked glycosylation, for which a Pro is preferred one position in front of or 3 positions behind Ser or Thr (45) , as the OG domain is composed of 12 repeats of the sequence Thr/Ser-Xxx-Xxx-Pro. In natural MMP-9 isolated from human neutrophils, the O-linked sugars consist of the classical core 1 (Gal-GalNAc-O-Ser) or core 2 (Gal-(GlcNAc-)GalNAc-O-Ser) structures which are further elongated to relatively large glycans, consisting of up to 10 monosaccharide residues (10) . Such oligosaccharides may have various functions and may e.g. shield the protein backbone against proteolysis (45) . The O-linked glycans in the recombinant variants of MMP-9 contain, however, only basic structures with 1 or 2 monosaccharides (GalNAc-O-Ser and Gal-GalNAc-O-Ser). Since this could lead to functional differences, comparison with natural MMP-9 isolated from human neutrophils and, where applicable, with the MMP-9-TIMP-1 complex isolated from the monocytic leukaemia cell line THP-1 was performed to detect possible functions of the full-length glycans. Comparison between the recombinant full-length variant and deletion mutants allowed for a further dissection of the role of the protein part of the OG-domain with the basic monosaccharide structures. Since little information was available on the overall 3D structure of the OG domain, a combined strategy of in silico modelling and experimental analysis of sedimentation coefficients was used to gain information on the overall 3D structure of the OG domain. This indicated that the structure of the OG domain is unique and not extended (such as in mucins) but rather more compact, and is consistent with the proposal that Cys 468 in the OG domain may form a disulfide bridge with Cys674 in the hemopexin domain. This disulfide bridge, however, remains to be proven.
Deletion of the OG and/or hemopexin domains did not influence significantly the cleavage of a number of known substrates of MMP-9, excluding the possibility that these two domains contain exosites for these substrates. In contrast, both domains play a key role in the biological regulation of MMP-9. It has been known for some time that TIMP-1 binds to the carboxyterminal part of proMMP-9 (6;48). The OG domain is shown here to influence the binding of TIMP-1 to the hemopexin domain, as deletion of the OG domain results in decreased affinity for TIMP-1. Down-regulation of MMP-9 also occurs by internalisation and catabolism after binding to LRP-1 (7). By surface plasmon resonance analysis, the hemopexin domain is found to be essential for this binding. The OG domain is also important for this binding, since its deletion leads to a 10-fold decrease in affinity. The main differences between MMP-9∆OG and the full-length forms in the binding to TIMP-1 and LRP-1 reside in the k on rate, which is concentration-dependent. This is not likely to be caused by misfolding of MMP-9∆OG, since its catalytical activity is similar to that of MMP9fl. It may rather indicate that the binding sites for TIMP-1 and LRP-1 in the hemopexin domain are less accessible, suggesting that the OG domain is required for the correct orientation of the hemopexin domain. However, TIMP-1 and LRP-1 probably do not compete for binding to MMP-9, since the proMMP-9-TIMP-1 complex binds to LRP-1 with the same affinity as intact proMMP-9. In addition, internalisation studies showed for the first time that megalin/LRP-2 is a functional endocytosis receptor for MMP-9. Binding, uptake and chloroquine/leupeptin-sensitive degradation of MMP-9 by immortalized megalin-expressing BN16 rat yolk sac cells was inhibitable by RAP and anti-megalin antibodies. Whether endocytosis of MMP-9 is mediated in vivo by LRP-1 and/or by megalin, is likely to be dependent on the local expression levels of both receptors. It is therefore tempting to speculate that megalin will account for the endocytosis of MMP-9 in epithelial tissues such as the visceral yolk sac and renal proximal tubules, where megalin is predominantly expressed (49) . LRP-1 is more predominant in the liver and on macrophages (50) . By means of surface plasmon resonance, it was found that MMP-9 binds directly to megalin and that the hemopexin domain of MMP-9 is essential for this binding. Also the OG domain was important to confer high affinity to megalin/LRP-2, suggesting that the hemopexin domain orientation by the OG domain might be a common mechanism for efficient inhibition by TIMP-1 and receptormediated internalisation of MMP-9 by LRP-1 and megalin. Both mechanisms may contribute as negative feedback in the regulation of the bioavailability of proteolytically active MMP-9. Hemopexin domains in MMPs have a significant homology with hemopexin, which is abundantly present in plasma. The main function of hemopexin is to capture free heme that may be liberated in plasma upon red blood cell lysis, as free heme diplays strong inflammatory and toxic properties. Recently, the endocytotic receptor for the hemopexin-heme complex was identified as LRP-1 (36) . The present findings show that the hemopexin domain of MMP-9 also binds LRP-1. Since this binding is the only known function shared by both hemopexin itself and the MMP hemopexin domains, it may be assumed that binding to LRP-1 was the primary function of the hemopexin domain in MMPs during evolution. In MMP-2 and MMP-13, which do not contain an OG domain, the binding of the hemopexin domain to LRP-1 involves indirect mechanisms and other molecules. The binding of gelatinase A/MMP-2 to LRP-1 is significantly enhanced by complex formation with either thrombospondin-1 or -2 or with TIMP-2 (51;52). In the case of MMP-13, an unknown 170 kDa receptor first binds proMMP-13 to the cell surface and subsequently transfers the enzyme to LRP-1 for internalisation and degradation (53) . As a comparison, no such indirect or enhancing mechanisms have been described for MMP-9 to date, but the hemopexin domain function of MMP-9 may have been further refined by natural selection into a molecular domain with a defined orientation through the OG domain. Another function for the hemopexin domain was demonstrated recently and consists of the localisation of gelatinase B/MMP-9 to the membrane by binding to a membrane-bound receptor, the DNA repair protein Ku (54) . As a conclusion, analysis of recombinant variants of MMP-9 shows that the hemopexin domain is essential for the interaction between MMP-9 and LRP-1 and megalin. In addition, it is documented for the first time that megalin is a new functional endocytosis receptor for MMP-9. Furthermore, a biological function of the unique OG domain of MMP-9 is found. This domain with abundant O-linked glycans and a single cysteine residue is important for an optimal binding of the hemopexin domain to the inhibitor TIMP-1 and the two internalisation cargo receptors, LRP-1 and megalin, thus regulating the bio-availability of active MMP-9. The different recombinant MMP-9 variants, depicted in panel A, were produced in Sf9 insect cells with a baculoviral transfection system. After purification, the variants were analysed by reducing and non-reducing SDS-PAGE to estimate the molecular weights and to visualize di-and multimerisation, respectively. Nat MMP-9, natural MMP-9 isolated from human neutrophils; St, molecular weight reference standard. The binding of MMP-9 variants to LRP-1 was analysed by surface plasmon resonance. The different variants are indicated in the graphs and included natural neutrophil MMP-9, which is partially complexed to NGAL, THP-1 MMP-9, which is complexed to TIMP-1, and the different recombinant variants. Different concentrations of each MMP-9 variant were used (from top to bottom in each graph: 500 nM, 200 nM, 100 nM, 50 nM, 20 nM, 10 nM and 5 nM). The dissociation constants (Kd) were calculated from the binding curves and are indicated in Table 4 . 125 Ilabeled MMP-9fl after 4 hours of incubation in presence of RAP (100 µg/ml), rabbit anti-megalin IgG (100 µg/ml) or non-immune IgG (100 µg/ml). (D-F) Similar experiments as in (A-C) using natural 125 I-labeled MMP-9 as radioligand. All values are the measured radioactivity in percent of the added radioactivity and are the mean ± 1 SD of triplicate determinations. Total uptake in (C) and (F) is the sum of degraded and cell-associated radioactivity. Figure 9 . Binding of MMP-9 variants to megalin The binding of MMP-9 to megalin/LRP-2 was analysed by surface plasmon resonance. Different proMMP-9 variants, indicated in the graphs, were used, including the domain deletion mutants to assess the role of the OG and hemopexin domains. Furthermore, natural neutrophil MMP-9, which is partially complexed to NGAL, a known ligand of megalin, and THP-1 MMP-9, which is complexed to TIMP-1, were also included to evaluate the effects of the respective complex formations. Different concentrations of each MMP-9 variant were used (from top to bottom in each graph: 500 nM, 200 nM, 100 nM, 50 nM, 20 nM, 10 nM and 5 nM). The dissociation constants (Kd) were calculated from the binding curves and are indicated in Table 5 . 
